tiprankstipranks

Kim Janda Insider Profile

4 Followers
Kim Janda, Director at Sorrento Therapeutics, holds 3.00K shares in Sorrento Therapeutics (Ticker: SRNEQ).
tipranks
Kim Janda

Kim Janda
Sorrento Therapeutics (SRNEQ)
Director

Not Ranked
Kim Janda has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$60
100.00%
A breakdown of Kim Janda's holdings

Insider Roles

Sorrento Therapeutics
(SRNEQ)
Director
Roles that Kim Janda holds in companies

Most Profitable Insider Trade

Stock:
Sorrento Therapeutics
(SRNEQ)
Rating:Informative Buy
Date:Feb 03, 2017 - Feb 03, 2018
Return:+50.00%
The most profitable trade made by Kim Janda

Kim Janda's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Sorrento Therapeutics
Dec 27, 2021
Director
Uninformative Sell
17.64K
$60.00
Success Rate for
SRNEQ
1 out of 1 profitable transactions on
SRNEQ
100%
Average Return for
SRNEQ
Average return per transaction on
SRNEQ
+50.00%
Date
Transaction
Amount
No. of Shares
Price per Share
Profit
Link to Report
Feb 03, 2017
Informative Buy
$15.45K
-
$5.15
+50.00%
Apr 15, 2021
Uninformative Sell
$13.24K
-
$3.50
Sep 28, 2021
Uninformative Sell
$339.70K
-
$2.10
Dec 27, 2021
Uninformative Sell
$17.64K
-
$4.00
List of latest transactions for each holding click on a transaction to see Kim Janda's performance on stock

Kim Janda insider profile FAQ

What is the percentage of profitable transactions made by Kim Janda?
The percentage of profitable transactions made by Kim Janda is ―.
    What is the average return per transaction made by Kim Janda?
    The average return per transaction made by Kim Janda is ―.
      What stocks does Kim Janda hold?
      Kim Janda holds: SRNEQ stocks.
        What was Kim Janda’s latest transaction?
        Kim Janda latest transaction was an Uninformative Sell of $17.64K.
          What was Kim Janda's most profitable transaction?
          Kim Janda’s most profitable transaction was an Informative Buy of SRNEQ stock on February 3, 2017. The return on the trade was 50.00%.
            What is Kim Janda's role in Sorrento Therapeutics?
            Kim Janda's role in Sorrento Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.